Literature DB >> 2480642

Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer.

E H Nardin1, D A Herrington, J Davis, M Levine, D Stuber, B Takacs, P Caspers, P Barr, R Altszuler, P Clavijo.   

Abstract

T cell clones obtained from a human volunteer immunized with Plasmodium falciparum sporozoites specifically recognized the native circumsporozoite (CS) antigen expressed on P. falciparum sporozoites, as well as bacteria- and yeast-derived recombinant falciparum CS proteins. The response of these CD4+ CD8- cells was species-specific, since the clones did not proliferate or secrete gamma interferon when challenged with sporozoites or recombinant CS proteins of other human, simian, or rodent malarias. The epitope recognized by the sporozoite-specific human T cell clones mapped to the 5' repeat region of the CS protein and was contained in the NANPNVDPNANP sequence.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2480642     DOI: 10.1126/science.2480642

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  21 in total

1.  Mapping of specific and promiscuous HLA-DR-restricted T-cell epitopes on the Plasmodium falciparum 27-kilodalton sexual stage-specific antigen.

Authors:  C E Contreras; I N Ploton; R F Siliciano; C L Karp; R Viscidi; N Kumar
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

2.  A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.

Authors:  A Birkett; K Lyons; A Schmidt; D Boyd; G A Oliveira; A Siddique; R Nussenzweig; J M Calvo-Calle; E Nardin
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.

Authors:  J Mauricio Calvo-Calle; Giane A Oliveira; Carol Othoro Watta; Jonathan Soverow; Carlos Parra-Lopez; Elizabeth H Nardin
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

4.  Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

Authors:  Elizabeth H Nardin; Giane A Oliveira; J Mauricio Calvo-Calle; Kristiane Wetzel; Carolin Maier; Ashley J Birkett; Pramod Sarpotdar; Michael L Corado; George B Thornton; Annette Schmidt
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.

Authors:  Kavita Tewari; Barbara J Flynn; Silvia B Boscardin; Kathrin Kastenmueller; Andres M Salazar; Charles A Anderson; Velmurugan Soundarapandian; Adriana Ahumada; Tibor Keler; Stephen L Hoffman; Michel C Nussenzweig; Ralph M Steinman; Robert A Seder
Journal:  Vaccine       Date:  2010-09-21       Impact factor: 3.641

6.  Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Authors:  Daniel Carapau; Robert Mitchell; Adéla Nacer; Alan Shaw; Caroline Othoro; Ute Frevert; Elizabeth Nardin
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

7.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

8.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

9.  Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.

Authors:  Caroline Othoro; Dean Johnston; Rebecca Lee; Jonathan Soverow; Jean-Claude Bystryn; Elizabeth Nardin
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

10.  Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax.

Authors:  Y Zevering; C Khamboonruang; K Rungruengthanakit; L Tungviboonchai; J Ruengpipattanapan; I Bathurst; P Barr; M F Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.